Pharmacokinetics of solithromycin (CEM-101) after single or multiple oral doses and effects of food on single-dose bioavailability in healthy adult subjects.
about
Emergence of multidrug-resistant, extensively drug-resistant and untreatable gonorrheaA New, Potent, and Placenta-Permeable Macrolide Antibiotic, Solithromycin, for the Prevention and Treatment of Bacterial Infections in PregnancyCurrent and future antimicrobial treatment of gonorrhoea - the rapidly evolving Neisseria gonorrhoeae continues to challengeIn vitro activity of the new fluoroketolide solithromycin (CEM-101) against macrolide-resistant and -susceptible Mycoplasma genitalium strains.Investigational antimicrobial agents of 2013.In vitro and in vivo activity of solithromycin (CEM-101) against Plasmodium speciesType III Secretion-Dependent Sensitivity of Escherichia coli O157 to Specific KetolidesSafety and Pharmacokinetics of Solithromycin in Subjects with Hepatic ImpairmentIn vitro activity of the new fluoroketolide solithromycin (CEM-101) against a large collection of clinical Neisseria gonorrhoeae isolates and international reference strains, including those with high-level antimicrobial resistance: potential treatmComparison of plasma, epithelial lining fluid, and alveolar macrophage concentrations of solithromycin (CEM-101) in healthy adult subjects.Solithromycin Pharmacokinetics in Plasma and Dried Blood Spots and Safety in Adolescents.Randomized, double-blind, multicenter phase 2 study comparing the efficacy and safety of oral solithromycin (CEM-101) to those of oral levofloxacin in the treatment of patients with community-acquired bacterial pneumonia.Efficacy of Solithromycin (CEM-101) for Experimental Otitis Media Caused by Nontypeable Haemophilus influenzae and Streptococcus pneumoniaeMaternal administration of solithromycin, a new, potent, broad-spectrum fluoroketolide antibiotic, achieves fetal and intra-amniotic antimicrobial protection in a pregnant sheep model.Antibiotics in development targeting protein synthesis.Small molecule anti-malarial patents: a review (January 2010-June 2011).Renaissance of antibiotics against difficult infections: Focus on oritavancin and new ketolides and quinolones.Update on Treatment Options for Gonococcal Infections.The role of solithromycin in the management of bacterial community-acquired pneumonia.Antimicrobial-resistant sexually transmitted infections: gonorrhoea and Mycoplasma genitalium.Solithromycin (CEM-101): A New Fluoroketolide Antibiotic and Its Role in the Treatment of Gonorrhea.Nature nurtures the design of new semi-synthetic macrolide antibiotics.Solithromycin: A Novel Fluoroketolide for the Treatment of Community-Acquired Bacterial Pneumonia.Antimicrobial activity of solithromycin against clinical isolates of Legionella pneumophila serogroup 1.Solithromycin for the treatment of community-acquired bacterial pneumonia.New treatment options for lower respiratory tract infections.The wobbly status of ketolides: where do we stand?Spotlight on solithromycin in the treatment of community-acquired bacterial pneumonia: design, development, and potential place in therapy.Development of an Adult Physiologically Based Pharmacokinetic Model of Solithromycin in Plasma and Epithelial Lining Fluid.
P2860
Q24633203-22C54AF5-377F-4DB9-A935-64E8061E5630Q26749565-21F23319-FA8F-48CE-8F63-FA8DF14C3006Q26796265-EA5E6CCA-1E03-4709-A9C8-E00E4FB99A20Q33797838-94211818-6D89-415D-82F1-42B62AAD3889Q34375204-F3F77DCF-7710-447A-9EB5-8B5E92E50BA1Q35689416-48895260-F530-46BF-B5ED-A052491C9783Q35829561-AD533C0A-764D-4D6B-8B9C-BDA4ED5D253FQ35860106-F9F79A16-301D-42AF-8B24-F2EE8AC5B26AQ35941481-AD4900CA-791A-4BBF-B1C3-DEB94368F5D3Q36276911-6F0CA9B3-B8F7-4638-8FE7-FCEF5C8D6F02Q36730079-4BF13A5E-6B2C-4A25-BFE1-459CE5940663Q37026706-5528B4BB-FA79-41B0-B167-A2FEC2C7D4A5Q37203789-E6F6A29A-063D-4BBE-BB62-C57E27DFA1E2Q37544439-2160FB5B-7863-4138-B875-1988696839E1Q37970724-D38D6716-E508-4E65-8590-60A758337395Q38018392-2AA70669-CAF5-41BE-8897-6573ADEEAFDCQ38233471-B396A013-CA65-49E2-829B-811803E5E5BCQ38581807-0B5AFC4A-F138-48AC-9B28-14AAE7542EEBQ38723961-74D7E488-700F-496B-AF71-ED8A07CFE643Q38772340-4182F956-5BBF-4479-B25B-3FBB52094B92Q38793951-237AAC64-870A-4B55-809B-7B06B2512146Q39023947-1E1B50A6-D16A-49DC-83B9-ABCE0060C5EFQ39026738-D2E84207-1DDA-4F72-ABD6-BEB1114393BBQ39054852-747D806F-63D9-42C1-B4B4-F837A4B3D0A7Q39278428-9AE733DC-3F74-4335-B654-78E1FAB7AE5BQ40111519-13DE5414-50CE-4F6B-B49D-2F3EEE8C4895Q43408523-2ADDC47C-DC87-415D-87C6-EDCAB23FF971Q47119741-305FEC94-FEF7-4296-9993-D03D77ED1609Q47134454-CD908EAD-DCA9-4D0A-871C-87765CB6C2AB
P2860
Pharmacokinetics of solithromycin (CEM-101) after single or multiple oral doses and effects of food on single-dose bioavailability in healthy adult subjects.
description
2011 nî lūn-bûn
@nan
2011 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Pharmacokinetics of solithromy ...... ity in healthy adult subjects.
@ast
Pharmacokinetics of solithromy ...... ity in healthy adult subjects.
@en
Pharmacokinetics of solithromycin
@nl
type
label
Pharmacokinetics of solithromy ...... ity in healthy adult subjects.
@ast
Pharmacokinetics of solithromy ...... ity in healthy adult subjects.
@en
Pharmacokinetics of solithromycin
@nl
prefLabel
Pharmacokinetics of solithromy ...... ity in healthy adult subjects.
@ast
Pharmacokinetics of solithromy ...... ity in healthy adult subjects.
@en
Pharmacokinetics of solithromycin
@nl
P2093
P2860
P356
P1476
Pharmacokinetics of solithromy ...... ity in healthy adult subjects.
@en
P2093
Drusilla Scott
J Gordon Still
Jennifer Schranz
Maria J Gutierrez
Prabhavathi Fernandes
Thorsten P Degenhardt
P2860
P304
P356
10.1128/AAC.01429-10
P407
P577
2011-01-31T00:00:00Z